Thomas Ross
Sales & Marketing chez MAXCYTE, INC.
Fortune : 92 250 $ au 30/04/2024
Profil
Thomas Michael Ross is currently the Executive Vice President-Global Sales & Marketing at MaxCyte, Inc. He previously worked as the Operations Director at Life Technologies Corp., Principal at Cambrex Corp.
and Lonza Walkersville, Inc., Chief Commercial Officer at Predictive Biosciences, Inc., VP-North America Medical Diagnostics Sales at Digene Corp., and Senior Vice President-Commercial Operations at OpGen, Inc. He obtained his undergraduate degree from The Citadel, The Military College of South Carolina.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MAXCYTE, INC.
0,02% | 15/03/2024 | 25 000 ( 0,02% ) | 92 250 $ | 30/04/2024 |
Postes actifs de Thomas Ross
| Sociétés | Poste | Début |
|---|---|---|
| MAXCYTE, INC. | Sales & Marketing | 15/10/2014 |
Anciens postes connus de Thomas Ross
| Sociétés | Poste | Fin |
|---|---|---|
| OPGEN, INC. | Corporate Officer/Principal | 01/09/2014 |
Predictive Biosciences, Inc.
 Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | Corporate Officer/Principal | 01/06/2012 |
Digene Corp.
 Digene Corp. Electronic Equipment/InstrumentsElectronic Technology Digene Corp. developed manufactured and market DNA and RNA tests. Its products are used for the detection, screening and monitoring of human diseases. The company was founded by Floyd E. Taub and Evan Jones in 1987 and was headquartered in Germantown, MD. | Sales & Marketing | 01/09/2007 |
| CAMBREX CORPORATION | Corporate Officer/Principal | - |
Lonza Walkersville, Inc.
 Lonza Walkersville, Inc. Pharmaceuticals: MajorHealth Technology Lonza Walkersville, Inc. develops, manufactures and provides testing services for cell-based therapeutics. Its services include life-science customers, research organizations, pharmaceutical, biopharmaceutical, biotechnology and generic drug companies. The company was founded was founded on May 9, 1991 and is headquartered in Walkersville, MD. | Corporate Officer/Principal | - |
Formation de Thomas Ross
| The Citadel, The Military College of South Carolina | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| OPGEN, INC. | Commercial Services |
| MAXCYTE, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Predictive Biosciences, Inc.
Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | Health Services |
Digene Corp.
Digene Corp. Electronic Equipment/InstrumentsElectronic Technology Digene Corp. developed manufactured and market DNA and RNA tests. Its products are used for the detection, screening and monitoring of human diseases. The company was founded by Floyd E. Taub and Evan Jones in 1987 and was headquartered in Germantown, MD. | Electronic Technology |
Life Technologies Corp.
 Life Technologies Corp. Miscellaneous Commercial ServicesCommercial Services Life Technologies Corp. provides products in the areas of scientific research, genetic analysis and applied sciences. Its brands include Invitrogen, Applied Biosystems, Gibco, Molecular Probes, Noves, Ambion and Ion Torrent. The firm’s portfolio includes the most cited products and technologies in qPCR, capillary electrophoresis sequencing, nextgeneration sequencing, molecular diagnostics, forensics, cell culture and analysis, and agriculture research. The company was founded on November 21, 2008 and is headquartered in Carlsbad, CA. | Commercial Services |
Lonza Walkersville, Inc.
Lonza Walkersville, Inc. Pharmaceuticals: MajorHealth Technology Lonza Walkersville, Inc. develops, manufactures and provides testing services for cell-based therapeutics. Its services include life-science customers, research organizations, pharmaceutical, biopharmaceutical, biotechnology and generic drug companies. The company was founded was founded on May 9, 1991 and is headquartered in Walkersville, MD. | Health Technology |
Cambrex Corp.
 Cambrex Corp. Pharmaceuticals: GenericHealth Technology Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates. The company was founded by Arthur Mendolia and Cyril C. Baldwin Jr. in 1981 and is headquartered in East Rutherford, NJ. | Health Technology |
